Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksQinetiq Regulatory News (QQ.)

Share Price Information for Qinetiq (QQ.)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 444.00
Bid: 443.60
Ask: 444.20
Change: -5.40 (-1.20%)
Spread: 0.60 (0.135%)
Open: 450.60
High: 450.60
Low: 441.80
Prev. Close: 449.40
QQ. Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Third Quarter Trading Update

10 Feb 2016 07:00

RNS Number : 5803O
QinetiQ Group plc
10 February 2016
 

10 February 2016

 

QinetiQ Group plc

 

Third Quarter Trading Update

 

QinetiQ Group plc ('QinetiQ') today issues a third quarter trading update and reaffirms previous guidance for Group performance in the full year to 31 March 2016.

Trading Environment

The UK defence market remains uncertain. While the Government's Strategic Defence and Security Review was published in December 2015, it is likely to take some time before its impact is clear. Additionally, the Single Source Regulations Office (SSRO) is not expecting to publish the single source profit rate for the next financial year until March 2016.

EMEA Services

The performance of EMEA Services was in line with expectations in the period and revenue under contract for this financial year is as anticipated at this stage, but the division has continued to experience some de-scoping and delay to orders. During the period, EMEA Services won a contract with Motorola Solutions to provide monitoring, assessment and assurance services in support of the delivery of the UK Emergency Services Network. As announced in November 2015, it also secured a £153m five-year renewal from the UK Ministry of Defence (MOD) for aircraft engineering support.

In December, QinetiQ sold Cyveillance Inc. to Looking Glass Cyber Solutions Inc. for net disposal proceeds of £22m. Cyveillance is a former business unit of the US Services division, sold in May 2014, and more recently has been reported in EMEA Services. In the full year to 31 March 2015, it had revenues of $18m.

Global Products

Trading in Global Products was as expected during the period, and revenue under contract for this financial year is as anticipated at this stage, but its performance remains dependent on the timing and shipment of key orders in what is a shorter order cycle business.

Among the division's new orders in the period, the OptaSense business was awarded a contract to protect approximately 2,000km of pipeline which, once installed, will be the world's largest distributed fibre sensing project. The total value of the project is more than $30m of which approximately half has been contracted with OptaSense.

Outlook

Overall, the Board's expectations for Group performance in the current financial year remain unchanged from those set out in QinetiQ's interim results announcement dated 19 November 2015. ENDS

 

Notes to Editors:

QinetiQ will announce its preliminary annual results on 26 May 2016.

 

Download the QinetiQ investor relations app for iPad and iPhone from the App Store.

 

A FTSE250 company, QinetiQ uses its world class knowledge, research and innovation to provide high-end technical expertise and advice, to customers in the global aerospace, defence and security markets. QinetiQ's unique position enables it to be a trusted partner to government organisations, predominantly in the UK and the US, including defence departments as well as other international customers in targeted sectors.

For more information see www.QinetiQ.com

Follow us on twitter @QinetiQ

For further information please contact:

 

Investor relations:

David Bishop, QinetiQ

+44 (0) 7920 108675

Media relations:

QinetiQ press office

+44 (0) 1252 393500

Chris Barrie, Citigate Dewe Rogerson

+44 (0) 7968 727289

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTDKLFBQLFXBBD
Date   Source Headline
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20241:54 pmRNSDirector Declaration
5th Mar 202412:08 pmRNSDirector Declaration
5th Mar 20247:00 amRNSTransaction in Own Shares
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20247:00 amRNSTransaction in Own Shares
29th Feb 20244:00 pmRNSTotal Voting Rights
29th Feb 20247:00 amRNSTransaction in Own Shares
28th Feb 20247:00 amRNSTransaction in Own Shares
27th Feb 20247:00 amRNSTransaction in Own Shares
26th Feb 20247:00 amRNSTransaction in Own Shares
23rd Feb 20247:00 amRNSTransaction in Own Shares
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 20247:00 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20247:00 amRNSTransaction in Own Shares
15th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSTransaction in Own Shares
13th Feb 20247:00 amRNSTransaction in Own Shares
9th Feb 20249:32 amRNSHolding(s) in Company
9th Feb 20247:00 amRNSTransaction in Own Shares
8th Feb 20247:00 amRNSTransaction in Own Shares
6th Feb 202411:55 amRNSResult of Meeting
5th Feb 20243:48 pmRNSDirector/PDMR Shareholding
19th Jan 20249:31 amRNSDirector/PDMR Shareholding
16th Jan 20247:00 amRNSQ3 Trading Update and Share Buyback Programme
10th Jan 20245:00 pmRNSDirector/PDMR Shareholding
12th Dec 20232:38 pmRNSDirector/PDMR Shareholding
12th Dec 20232:32 pmRNSDirector Declaration
22nd Nov 20238:29 amRNSHolding(s) in Company
20th Nov 20237:00 amRNS$170m US new business contract win
16th Nov 20237:00 amRNSInterim Results
13th Nov 20239:58 amRNSDirector/PDMR Shareholding
25th Oct 20237:23 amRNSInvestor Seminar
17th Oct 20238:00 amRNSDirector Declaration
11th Oct 20237:00 amRNSSecond Quarter Trading Update
10th Oct 20233:56 pmRNSDirector/PDMR Shareholding
4th Oct 20237:00 amRNS$127m contract win in the US (formerly Avantus)
3rd Oct 20237:00 amRNS$84m contract win in the US
28th Sep 20233:24 pmRNSDirector/PDMR Shareholding
12th Sep 20235:54 pmRNSDirector/PDMR Shareholding
31st Aug 20235:03 pmRNS$224m contract win in the US (formerly Avantus)
25th Aug 20232:23 pmRNSDirector/PDMR Shareholding
10th Aug 20234:31 pmRNSDirector/PDMR Shareholding
27th Jul 20234:45 pmRNSDirector/PDMR Shareholding
20th Jul 20232:00 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.